Evry, France – September 20, 2017
ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, announced today that the Company is moving its research laboratories to Genopole, a leading biocluster dedicated to biotechnology and research in genomics and genetics. The new laboratories brings Enterome closer to its existing and potential new partners and provides opportunities to extend its scientific expertise and network to develop its business further.
About 15 of the 40 people employed by Enterome will work permanently at Genopole in laboratories dedicated to the discovery and development of innovative therapeutic products derived from the gut microbiome.
Pierre Belichard, CEO of Enterome, said: “The strategic relocation of our laboratories is a key step for developing our technology platform. Genopole is recognised internationally for the quality of its facilities and the professionalism of the technical team, which was a key factor in our decision to make our research headquarters at Genopole.”
The gut microbiome makes an important contribution to maintaining an individuals’ health as it plays a crucial role in building natural immunity. The latest discoveries have allowed the scientific community to characterise some of the functions of the gut bacteria and the understanding of the relationship between the microbiome and human health is becoming more and more important for the development of a new generation of drugs and diagnostics.
Understanding the mechanism of diseases linked to the dysfunction of the gut microbiome is at the heart of Enterome’s metagenomics research platform. By studying the key molecular mechanisms of the bacteria/host interaction, Enterome believes it can use this information to develop innovative drugs and diagnostics that will provide patients with better outcomes to their diseases.
Jean-Marc Grognet, CEO of Genopole, said: “We are delighted to welcome Enterome to our laboratories facilities at Genopole. The study of the microbiome is very important for understanding diseases such as Crohn’s disease, cancers, diabetes, gastro-intestinal disorders and metabolic diseases; and is aligned with our strategy to support research that reflects personalised medicine.”
The Company was established in 2012 in Paris (France) to develop the discoveries made by the INRA metagenomic platform, and is backed by leading venture capital investors (Seventure Partners, Lundbeckfonden Ventures, Health for Life Capital & Omnes Capital) and strategic investors (Nestlé Health Science, BMS, Shire & INRA Transfert).
Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel and gastro-intestinal diseases; Bristol-Myers Squibb in immuno-oncology; and the Mayo Clinic and Geisinger hospitals in metabolic disorders.
Enterome is in a 50/50 joint venture with Nestlé Health Science, called Microbiome Diagnostics Partners, focused initially on the development of novel microbiome-based diagnostics for IBD and liver diseases.
Additional information about Enterome is available through its website: www.enterome.com
Genopole is France’s leading biocluster dedicated to biotechnology and research in genomics and genetics, with 86 biotechnology companies, 19 research laboratories, 25 technology platforms as well as university courses (université d’Evry-Val-d’Essonne). Its objective is to create and support biotechnology companies and technology transfer towards industry, help the development of life science research and develop top level courses in this field. Genopole is mainly supported by the French government, the Ile-de-France region, the Essonne department, the agglomération Grand Paris Sud, the city of Evry and the AFM-Telethon. www.genopole.fr
Pierre Belichard, CEO
+33 1 75 77 27 87
Anne Rohou, Communication Department
Tel. +33 1 60 87 83 10
Mark Swallow / Marine Perrier / David Dible
Citigate Dewe Rogerson
Tel. +44 207 638 9571 / firstname.lastname@example.org